Hospital at Home Monitoring: How Wearable Vital-Sign Trends Support Remote Clinical Review

Hospital at home brings acute, hospital-level treatment into the patient’s own home. Selected patients who would otherwise be admitted, for example, with an infection, a heart failure flare-up or a COPD exacerbation, are treated at home under the oversight of a hospital clinical team. 

The model moves the patient home, but not the ward. Home environments do not have the same monitoring infrastructure as inpatient rooms, and no single wearable meets every program requirement. The real question for program leaders is therefore not whether one device can replace the ward. It is where wearable information adds useful context without taking over the role of the program’s wider equipment, clinical oversight and care processes. 

This guide looks at hospital at home from that angle: what the model is, what published trials say about its cost, where wearable vital-sign trends fit into remote clinical review, and how to measure what a wearable actually contributes. 

At a glance 

• Who it is for: hospital-at-home and virtual ward program leads, clinical directors, nursing leads and virtual-care teams. 

• What wearables add: intermittent pulse rate, respiration rate and skin temperature trends, plus SpO2 with eBeat, which authorized professionals review alongside other patient information. 

• What they do not do: provide continuous surveillance or clinical alarms, or replace home visits, assessments, pathway equipment or the program’s escalation process. 

• What the evidence shows: hospital at home can lower the cost of a care episode, but results vary by setting, and the trials do not measure the value of any single device. 

• How to start: one program, one patient cohort and an agreed role for wearable data, with value measured against a baseline before expanding. 

What is hospital at home? 

Hospital at home is a care model in which selected patients who need hospital admission receive acute, hospital-level treatment in their own home instead of an inpatient bed, while a hospital clinical team remains responsible for their care. 

Care combines in-person and remote contact: nurse and physician home visits, intravenous medication, point-of-care testing, video communication and remote monitoring [1]. In the UK and parts of Europe, similar services often run under the name virtual wards. 

In the United States, the model has gained a longer planning horizon. The Acute Hospital Care at Home program, introduced by CMS in November 2020, allows approved hospitals to deliver and be paid for inpatient-level care at home. In February 2026, Congress extended it through September 30, 2030 [3], and many health systems are now moving from pilots to larger programs [4]. 

How hospital at home differs from other home monitoring 

Hospital at home is easy to confuse with other forms of remote patient monitoring at home. The difference lies in how unwell the patient is and who holds clinical responsibility. 

Because hospital-at-home patients are acutely ill, the monitoring question is also more demanding than in the other two settings. 

Where wearable trends fit in acute care at home 

In hospital at home, wearable vital-sign trends are one layer of clinical oversight, not the whole monitoring system. 

Clinical teams need to follow patient status and treatment response remotely while keeping clearly defined review and escalation workflows. Physiological trends are most useful when they sit alongside the other ways the team already learns how a patient is doing: 

Within this mix, wearables bring two practical benefits. First, pulse rate, respiration rate, skin temperature, and, with eBeat, SpO2 trends add context when clinicians review a patient’s status and response to treatment. Second, collecting selected measurements in a wearable form reduces dependence on fixed bedside equipment for those measurements, while the program keeps any other equipment the pathway requires. 

The limits matter just as much. Wearable trends do not provide continuous surveillance or clinical alarms, and they do not replace monitoring that the devices are not designed to provide. Clinical review and response remain part of the provider’s own care model. 

Device choice follows the pathway rather than defaulting to both devices. eBeat is arm-worn and adds SpO2 for pathways where oxygenation context is needed. eDoctor is chest-worn and suits pathways that do not require SpO2. 

If wearables are only one layer, how should their value be judged? The starting point is understanding what the hospital-at-home model as a whole can save.  

Does hospital at home save money? What the trials show 

Hospital at home can cost less than inpatient care, but published trials show that results depend on the setting and on how the program is run. 

Two randomized trials led by the same research group illustrate the range: 

Why the difference? In the rural trial, patients moved home relatively late in their stay, on average on day 4.2 of a 6.7-day episode, which the authors say likely reduced the effect on cost [2]. In other words, when and how patients move home is a program design decision, and it shapes the economics. 

Both trials also evaluated complete care models that combined home visits, treatment and remote monitoring. They show what a well-run program can achieve, but they do not establish the independent value of any monitoring device, including TEKTELIC’s. That distinction is the basis for a credible business case. 

Program savings vs the wearable’s own value 

Any savings attributed to a wearable should come from evaluation, not be borrowed from the full hospital-at-home program’s benefit. 

Potential value from hospital at home includes reduced inpatient bed use, lower cost per patient and greater program capacity. These are outcomes of the broader care program, not benefits a wearable can deliver on its own. A sound business case therefore answers two separate questions: 

Two principles keep the numbers reliable. First, released bed capacity, avoided costs and actual budget savings should be reported separately, because freeing a bed does not automatically reduce spending. Second, reductions in utilization, staffing or care costs should be confirmed against an agreed baseline rather than assumed. 

Program capacity deserves its own attention. Tracking patients supported, completed care episodes and caseload per clinical team shows whether wearable information helps keep caseloads manageable and staff activity focused, or whether review, visits or technical support become the factor that limits growth. 

How wearable trends reach remote clinical review 

Wearable data reaches clinicians through a gateway in the patient’s home, but decisions are made in the program’s own review and escalation workflow. 

How wearable trends reach remote clinical review 

Measurements travel over LoRaWAN through a preconfigured KONA Micro Gateway to the TEKTELIC application, so patients do not need to own, pair, charge or operate a smartphone. Our post-discharge article explains this setup in more detail. In the application, authorized professionals review current measurements and historical trends across their patients, then act through the program’s agreed workflow. 

Where a program needs the data in its existing clinical or virtual-care platform, the integration is scoped and validated before patients use it. Optional FINCH, VIVID or COMFORT devices can add call-for-help, presence, activity, door or environmental context. They remain secondary to eBeat and eDoctor and do not replace the program’s clinical escalation process. 

Decisions to make before the first patient goes home 

Acute episodes at home are short, so roles, rules and support need to be agreed before the first patient is enrolled, not worked out during the episode. 

Once these are in place, a focused start keeps risk and effort low: one hospital-at-home program, one defined patient cohort and an agreed role for wearable data. Before deployment, the team confirms home connectivity, wear comfort and baseline measures. Expansion follows only after patient acceptance, data delivery, staff workload, program fit and incremental value have been validated. 

Planning or scaling a hospital-at-home program? 

Contact TEKTELIC to discuss where wearable vital-sign trends could support remote clinical review in your pathway or explore TEKTELIC healthcare solutions.